What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Heart failure
Douglas L. Mann mainly investigates Internal medicine, Heart failure, Endocrinology, Tumor necrosis factor alpha and Heart disease.
He interconnects Placebo and Cardiology in the investigation of issues within Internal medicine.
His Heart failure research is multidisciplinary, relying on both Randomized controlled trial, Surgery and Immunology.
His Endocrinology research is multidisciplinary, incorporating elements of Proinflammatory cytokine and Cytokine.
His studies in Tumor necrosis factor alpha integrate themes in fields like Homeostasis, Interleukin 6, Myocyte, Cachexia and In vivo.
The various areas that Douglas L. Mann examines in his Heart disease study include Cornerstone, Hemodynamics, Cardiac output and Survival analysis.
His most cited work include:
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (3995 citations)
- Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine (1472 citations)
- The Seattle Heart Failure Model Prediction of Survival in Heart Failure (1440 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Tumor necrosis factor alpha.
His Internal medicine research incorporates elements of Endocrinology and Surgery.
His work carried out in the field of Heart failure brings together such families of science as Heart disease, Immunology, Clinical trial and Intensive care medicine.
His work in Cardiology tackles topics such as Stroke which are related to areas like Sinus rhythm.
Douglas L. Mann has researched Ejection fraction in several fields, including Placebo, Randomized controlled trial, Blood pressure and Hazard ratio.
His research in Tumor necrosis factor alpha intersects with topics in Cancer research, Cytokine, Pathogenesis, Receptor and Proinflammatory cytokine.
He most often published in these fields:
- Internal medicine (63.84%)
- Heart failure (57.61%)
- Cardiology (43.77%)
What were the highlights of his more recent work (between 2017-2021)?
- Heart failure (57.61%)
- Internal medicine (63.84%)
- Cardiology (43.77%)
In recent papers he was focusing on the following fields of study:
Douglas L. Mann mostly deals with Heart failure, Internal medicine, Cardiology, Ejection fraction and Ambulatory.
He combines subjects such as Clinical trial, Inflammation, Quality of life, Intensive care medicine and Cohort with his study of Heart failure.
Much of his study explores Internal medicine relationship to Placebo.
His Cardiology research integrates issues from Randomized controlled trial and Proportional hazards model.
His Ejection fraction research includes themes of Platelet aggregation inhibitor, Aspirin, Warfarin, Heart transplantation and Confidence interval.
He interconnects Ventricular assist device, Quality of life, Emergency medicine, Circulatory system and Transplantation in the investigation of issues within Ambulatory.
Between 2017 and 2021, his most popular works were:
- Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. (91 citations)
- The continuous heart failure spectrum: moving beyond an ejection fraction classification (75 citations)
- Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation (66 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Heart failure
His primary areas of study are Heart failure, Internal medicine, Ejection fraction, Cardiology and Cohort.
His Heart failure research is multidisciplinary, incorporating elements of Endocrinology, Quality of life, Adverse outcomes and Apolipoprotein B.
As part of his studies on Internal medicine, Douglas L. Mann often connects relevant areas like Physical interaction.
His research integrates issues of Clinical course, Disease management, Immunity and Heart transplantation in his study of Ejection fraction.
His biological study spans a wide range of topics, including Aspirin and Randomized controlled trial.
His work in Cohort covers topics such as Ambulatory which are related to areas like Emergency medicine and Ventricular assist device.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
